Abstract 1367P
Background
Alectinib has emerged as one of the anaplastic lymphoma kinase (ALK) directed therapy of choice in patients with advanced ALK+ non-small cell lung cancer (NSCLC). Body weight gain is a side effect reported in 12% of patients, caused by an increased amount of body fat. Baseline waist circumference has been found to be a positive predictor of the increase in visceral adipose tissue. We hypothesize that baseline body mass index (BMI) is positively associated with body weight gain.
Methods
Individual data from patients treated with alectinib were obtained via Vivli data-sharing platform. Studies with body weight data were selected. All body weight measurements during the first year of treatment were included. A mixed-effects model with random intercept was conducted to assess the trend of % change in body weight over time and to explore the effect of baseline characteristics on % change in body weight from baseline.
Results
Three prospective trials with body weight data were eligible (J-ALEX, ALUR, ML29453). All 309 patients were included in the analysis. During the first year of treatment, 2632 measurements of body weight were documented. Data from J-ALEX (n=103) was analyzed separately, as reference values for BMI differ between Japanese and Western populations. Percent change in body weight increased significantly over time in the mixed-model analyses in both J-ALEX (β = 0.48, p < 0.001) and ALUR/ML29453 (β = 0.31, p = 0.001). In the ALUR/ML29453 dataset there was an association between baseline albumin level and % change in body weight (β = 0.08, p = 0.003). A maximum body weight gain of ≥ 10% during the first year was observed in 23 patients (22.3%) in J-ALEX and 31 patients (15.0%) in ALUR/ML29453. Table: 1367P
Baseline characteristics
J-ALEX | ML29453 | MO28928 | |
n = 103 | n = 129 | n = 77 | |
Population | Japan | USA | Europe and Asia |
Baseline characteristics | |||
Age (in years) | 59 ± 14 | 55 ± 13 | 54 ± 12 |
Sex (M) (%) | 39.8 | 43.4 | 58.4 |
Weight (kg) | 55.9 [12.8] | 70.5 [19.6] | 70.0 [23.3] |
Baseline BMI (kg/m2) | 21.9 [3.8] | 24.1 [6.8] | 25.8 [5.7] |
Albumin baseline (g/L) | 39 [7] | 38 [6] | 37 [9] |
Conclusions
A significant and clinically relevant increase in body weight was observed in the first year of treatment with alectinib. Baseline BMI was not predictive for body weight gain. Informing patients before start of alectinib is strongly recommended.
Clinical trial identification
Trials included in analysis: J-ALEX trial, JO28928, JapicCTI-132316 ML29453, NCT02271139 ALUR trial, MO29759, CT02604342.
Editorial acknowledgement
This abstract is based on research using data that has been made available through Vivli, Inc. Vivli has not contributed to or approved, and is not in any way responsible for, the contents of this publication.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R.H. Mathijssen: Financial Interests, Institutional, Research Grant, Investigator-initiated research: Astellas, Bayer, Cristal Therapeutics, Pfizer, Roche, Sanofi, Servier, Boehringer Ingelheim, Novartis; Financial Interests, Institutional, Coordinating PI: Pamgene. E.F. van Rossum: Financial Interests, Personal, Research Grant: ElisabethFoundation, ZonMW/NWO. A-M.C. Dingemans: Financial Interests, Institutional, Advisory Board: Roche, Sanofi, Amgen, Bayer, Boehringer Ingelheim; Financial Interests, Institutional, Invited Speaker: Takeda, Lilly, Jansen, Pfizer, AstraZeneca; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Local PI: Lilly, Amgen, Daiichi Sankyo, JNJ, Mirati; Financial Interests, Institutional, Coordinating PI: Roche; Financial Interests, Institutional, Steering Committee Member: Roche; Non-Financial Interests, Other, Chair EORTC lung cancer group: EORTC; Non-Financial Interests, Member: IASCL, ASCO, AACR. All other authors have declared no conflicts of interest.
Resources from the same session
1037P - Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors
Presenter: Nicolas Mach
Session: Poster session 19
1039P - First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
Presenter: Geoffrey Ku
Session: Poster session 19
1040P - Phase I study of IL-8 inhibitor AMY109 plus atezolizumab (atezo) in patients (pts) with advanced solid tumours
Presenter: Yasutoshi Kuboki
Session: Poster session 19
1041P - Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with toripalimab in patients (pts) with advanced solid tumours
Presenter: Ben Markman
Session: Poster session 19
1042P - INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas
Presenter: Akin Atmaca
Session: Poster session 19
1043P - First-in-human study of TU2218, TGFβRI and VEGFR2 dual inhibitor in patients with advanced solid tumors
Presenter: Do-Youn Oh
Session: Poster session 19
1044P - A phase Ia first-in-human study of JS007, a novel anti-CTLA-4 monoclonal antibody, in patients with advanced solid tumors
Presenter: Jun Zhang
Session: Poster session 19
1045P - Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor
Presenter: Ravit Geva
Session: Poster session 19
1046P - Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results
Presenter: Jung Yong Hong
Session: Poster session 19